KALY - Kali-Extracts Financial Performance Update Tomorrow November 26, 2019
November 25 2019 - 10:33AM
InvestorsHub NewsWire
KALY - Kali-Extracts Financial
Performance Update Tomorrow November 26, 2019
Dallas, TX --
November 25, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced a management financial
performance update scheduled for release tomorrow, November 26,
2019. The update will be published in conjunction with KALY’s
financial performance report through September 30, 2019.
Management will highlight the company’s growing sales and
underlying asset value. Management intends to specifically
highlight the company’s potential to support the recently announced
strategy to independently finance the accelerated development and
expansion of its biopharmaceutical technology.
KALY has
recently announced receiving two inquiries into the acquisition of
the company’s cannabis biopharmaceutical technology valuing the
technology at $50 million. KALY management is entertaining
the inquiries but indicates that the $50 million valuation is too
low. KALY has a U.S. Patented Cannabis Extraction Process and
is developing treatments for various medical conditions (see
below). Doctors working with KALY on the treatment
developments have compared KALY’s technology to GW Pharmaceuticals’
and indicated the KALY solutions could be superior to GW
Pharma’s. KALY management has also recently announced that in
addition to entertaining the two acquisition opportunities that
could infuse financing that accelerates its cannabis extract
biopharmaceutical technology developments, that the company is
introducing a third option that would not involve a sale of KALY’s
biopharmaceutical technology asset, but would otherwise restructure
the asset within KALY’s current corporate structure to facilitate a
major infusion of investment capital. KALY management plans to
finalize the third option plans within the next two weeks and make
them public.
KALY’s cannabis
biopharmaceutical technology intellectual property portfolio
contains a deep pipeline of cannabinoid product candidates
including four distinct compounds listed
here:
Chronic Obstructive Pulmonary
Disease (COPD) - The
market for COPD treatment is anticipated to reach $14 billion by
2025;
Type 2
Diabetes - The market for
Type 2 Diabetes is expected to be a $64 billion market by
2026;
Cancer Pain
Management - The overall
pain management treatment market is anticipated to reach $83
billion by 2024, and
Epilepsy
- The market for epilepsy treatment is
anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted
and the next phase of research now moving forward, KALY recently
filed for a new patent application specifically on its formulation
for symptoms associated with COPD and other similar respiratory
conditions. KALY also filed for a trademark
on the name RespRx as the brand name for its CBD
formulation to treat the symptoms associated with COPD and other
similar respiratory conditions. The market
for COPD treatment is anticipated to reach $14 billion by
2025.
In addition to KALY’s ongoing efforts to develop
prescription therapies, KALY has initiated a program to certify its
proprietary CBD extracts derived from KALY’s U.S. Patented
Extraction Process as an Over-The-Counter (OTC) drug under the
requirements prescribed by the U.S. Food and Drug
Administration.
To stay abreast
of the latest developments and learn more about the company visit
https://www.kali-extracts.com/.
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024